Atalay, S., van den Reek, J. M., Otero, M. E., Njoo, M. D., Mommers, J. M., Ossenkoppele, P. M., … Kievit, W. (2020). Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. Acta Dermato-Venereologica, 100(19), 1–7. https://doi.org/10.2340/00015555-3692